The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

2011105 citationsJournal Articlebronze Open Access

Authors

Ruixin Liu · Johns Hopkins Medicine

Dingxie Liu · Johns Hopkins University

Eliana Trink · Johns Hopkins University

Ermal Bojdani · Johns Hopkins University

Guang Ning · Shanghai Jiao Tong University

Mingzhao Xing · Johns Hopkins Medicine

Abstract

Our study demonstrates a genetic selectivity of MK2206 in inhibiting thyroid cancer cells by targeting the PI3K/Akt pathway, supporting a clinical trial in thyroid cancer.

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Thyroid Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 96, Issue 4, pp. E577-E585

DOI: 10.1210/jc.2010-2644

Field-Weighted Citation Impact: 5.85